AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE - Generic Drug Details

What are the generic drug sources for azithromycin dihydrate; trovafloxacin mesylate and what is the scope of freedom to operate?

Azithromycin dihydrate; trovafloxacin mesylate is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TROVAN/ZITHROMAX COMPLIANCE PAK	azithromycin dihydrate; trovafloxacin mesylate	FOR SUSPENSION, TABLET;ORAL	050762-001	Dec 18, 1998		DISCN	No	No

Azithromycin Dihydrate and Trovafloxacin Mesylate: Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 1, 2026

Azithromycin dihydrate remains a large, mature generic antibiotic market supported by broad indications, oral and injectable formulations, global availability, and low manufacturing costs. Its branded revenue declined sharply after patent expiry, while generic volume has remained substantial. Trovafloxacin mesylate has no meaningful current commercial market. Pfizer withdrew Trovan after serious hepatotoxicity reports, and regulatory restrictions eliminated its viable revenue base.

What is the current market position of azithromycin dihydrate?

Azithromycin dihydrate is the dihydrate salt of azithromycin, a macrolide antibiotic marketed originally as Zithromax by Pfizer. It is available as tablets, capsules, oral suspension, extended-release suspension, and intravenous products. Approved uses include respiratory tract infections, sexually transmitted infections, skin infections, and selected pediatric infections.[1]

The market is mature and heavily genericized. In the United States, azithromycin is supplied by multiple manufacturers, including major generic companies and contract manufacturers. Competition is based primarily on price, supply reliability, dosage form, channel access, and hospital contracting rather than patent differentiation.

Market attribute	Azithromycin dihydrate
Originator brand	Zithromax, Pfizer
Drug class	Macrolide antibiotic
Principal dosage forms	Tablets, capsules, oral suspension, IV
U.S. market status	Generic and multisource
Patent position	Core composition and principal use patents expired
Main demand channels	Retail prescriptions, hospitals, pediatric care, international markets
Key commercial constraints	Low prices, antimicrobial stewardship, supply competition
Current commercial profile	High-volume, low-margin mature generic

Azithromycin demand increased temporarily during the COVID-19 pandemic despite a lack of established efficacy for COVID-19 treatment. Large-scale prescribing in 2020 and early 2021 lifted volumes in several markets. Subsequent clinical guidance and reduced off-label use returned demand closer to normal respiratory and infectious-disease patterns.[2]

How has the financial trajectory of azithromycin changed?

Azithromycin followed the standard small-molecule lifecycle: rapid branded growth, patent-protected pricing, loss of exclusivity, and long-term generic volume persistence.

Zithromax became one of Pfizer’s major anti-infective products during the 1990s and early 2000s. Revenue fell after generic entry following expiration of the primary U.S. patent estate. The brand retained some value through physician familiarity, pediatric formulations, global distribution, and hospital relationships, but it no longer controlled market pricing.

Ingredient-level financial reporting is limited because Pfizer and generic manufacturers generally report azithromycin within broader product or geographic categories. The financial trajectory is therefore best assessed through market structure and disclosed product events:

Period	Financial and commercial development
1990s	Strong branded growth following U.S. launch and broad indication expansion
Early 2000s	Core patent expiry and U.S. generic entry reduced branded pricing power
2000s-2010s	High generic volume continued, with declining unit economics
2020-2021	Temporary demand increase from COVID-19-related prescribing
2022 onward	Normalization of demand and continuing price pressure
Current market	Mature generic product with volume value but limited monopoly profit

The commercial value of azithromycin has shifted from patent rent to manufacturing scale. Companies with low-cost production, broad regulatory approvals, reliable active pharmaceutical ingredient supply, and established pharmacy distribution are better positioned than companies relying on premium pricing.

What patents protect azithromycin dihydrate?

The original azithromycin composition was protected in the United States by U.S. Patent No. 4,517,359, assigned to Pliva and related interests. The patent covered azithromycin compounds and expired in the early 2000s after statutory patent term adjustments and regulatory exclusivity periods were applied.[3]

Pfizer also held patents and regulatory rights associated with particular formulations, dosage forms, manufacturing processes, and uses. Those rights did not preserve long-term exclusivity over ordinary azithromycin tablets and oral suspension products.

What is the Orange Book status of azithromycin?

The FDA Orange Book historically included Zithromax and related azithromycin products, along with patents covering the reference products and selected formulations. The core active-ingredient protection is expired, and ordinary azithromycin products are now exposed to multisource generic competition.[4]

The residual patent value is narrow. It may relate to:

• Specific extended-release formulations.
• Particular suspension technologies.
• Manufacturing or crystallization processes.
• Device or packaging claims.
• Narrow method-of-use claims.

These rights do not recreate the broad market exclusivity once associated with Zithromax. A generic manufacturer targeting standard immediate-release tablets or conventional oral suspension generally faces a mature patent environment rather than a primary composition-patent barrier.

When did azithromycin lose exclusivity?

Azithromycin lost practical U.S. market exclusivity in the early 2000s. The principal composition patent expired around 2002, and generic entry followed. Regulatory exclusivity and pediatric extensions affected individual products and timing but did not materially change the long-term outcome.[3][4]

The commercial distinction is important:

1. Patent expiry ended the originator’s broad legal barrier.
2. Generic approvals converted the market from single-source to multisource supply.
3. Subsequent formulation patents covered narrower products.
4. Price erosion became the principal economic force.

Azithromycin therefore has no current small-molecule exclusivity comparable to a newly launched branded antibiotic.

Which companies compete in the azithromycin market?

Competition varies by country and dosage form. In the United States, generic suppliers have included Teva, Sandoz, Mylan, Lupin, Dr. Reddy’s Laboratories, Amneal, and other approved manufacturers over time. Pfizer remains associated with Zithromax, but the originator does not control the generic market.

International competition is broader. Indian, Chinese, European, and regional manufacturers supply azithromycin active pharmaceutical ingredient and finished dosage forms. Regulatory approval, pharmacopoeial compliance, stability data, and local registration determine market access.

The most commercially relevant competitive factors are:

• Cost of azithromycin API.
• Batch reliability and capacity.
• FDA, EMA, or other major-market approval.
• Ability to supply pediatric suspension.
• Hospital and wholesaler contracts.
• Product availability during respiratory-infection seasons.
• Compliance with antimicrobial stewardship requirements.

What are the generic entry risks for azithromycin?

The generic entry risk is already realized for standard azithromycin products. New entrants face commercial execution risk rather than patent risk.

A new manufacturer must compete against established suppliers in a low-price category. The principal risks are:

Risk	Commercial effect
Excess manufacturing capacity	Sustained price compression
API price volatility	Lower or negative gross margin
Pharmacy benefit substitution	Limited brand loyalty
Hospital tendering	Contract losses after price competition
Regulatory observations	Supply interruption or approval delay
Antimicrobial stewardship	Reduced inappropriate prescribing
Shortages at competing suppliers	Temporary opportunity for alternate manufacturers

Formulation-specific products can offer better economics, but they require differentiated regulatory filings, stability data, delivery technology, or channel access. Standard azithromycin tablets are unlikely to support premium pricing.

What is the market position of trovafloxacin mesylate?

Trovafloxacin mesylate is a fluoroquinolone antibiotic originally marketed by Pfizer under the brand name Trovan. The drug was approved in the United States in 1997 for selected bacterial infections, including serious respiratory, abdominal, pelvic, and skin infections.[5]

Its commercial trajectory ended after reports of severe liver injury, including hepatic failure and deaths. In 1999, the FDA restricted use of trovafloxacin and alatrofloxacin, its intravenous prodrug, to serious infections treated in hospitals when alternative antibiotics were unsuitable.[6] Pfizer subsequently withdrew Trovan from the U.S. market. European regulators also imposed restrictions and suspended or withdrew marketing authorization in relevant jurisdictions.[7]

Market attribute	Trovafloxacin mesylate
Originator	Pfizer
Brand	Trovan
Drug class	Fluoroquinolone
U.S. approval	1997
Major safety issue	Severe hepatotoxicity
U.S. regulatory action	Restricted use and market withdrawal
Current commercial market	Negligible
Generic opportunity	Economically unattractive
Principal barrier	Safety and regulatory status, not patent scope

Trovafloxacin does not have a viable conventional commercial trajectory. The limiting factor is not loss of patent protection. It is the product’s unfavorable risk-benefit profile and absence of meaningful market access.

What patents protected trovafloxacin mesylate?

Trovafloxacin was protected by Pfizer patents covering the quinolone compound, pharmaceutical compositions, and associated uses. The commercial value of those rights collapsed after safety-related regulatory intervention and withdrawal.

Even if relevant patents have expired or no longer create a practical barrier, generic entry would face substantial obstacles:

• Limited or absent demand.
• Regulatory scrutiny of hepatotoxicity.
• Restricted indications.
• Hospital-only or tightly controlled use.
• Product-liability exposure.
• Physician reluctance to prescribe.
• Difficulty establishing a favorable benefit-risk profile.

Patent expiry does not create a commercially attractive generic opportunity when regulators and prescribers have abandoned the product.

How does the patent estate of azithromycin compare with trovafloxacin?

Azithromycin has an expired but historically valuable patent estate. Trovafloxacin had a potentially valuable patent estate that became commercially irrelevant because of safety intervention.

Factor	Azithromycin dihydrate	Trovafloxacin mesylate
Core patent status	Expired	Historical rights largely no longer commercially relevant
Generic competition	Extensive	Minimal or absent
Current prescribing	Broad and recurring	Severely restricted or discontinued
Pricing	Low generic pricing	No meaningful market price
Manufacturing opportunity	Viable at scale	Weak
Regulatory risk	Routine generic compliance	Central commercial barrier
Revenue exposure	Ongoing generic volume	Effectively eliminated
Litigation risk	Limited routine patent disputes	Safety and regulatory history dominate

Azithromycin is a volume product. Trovafloxacin is a withdrawn product with no material modern market opportunity.

What regulatory status affects the financial outlook?

Azithromycin regulatory status

Azithromycin remains approved in multiple jurisdictions and is widely available as a generic. Its regulatory outlook is stable, subject to ordinary manufacturing, pharmacovigilance, labeling, and antimicrobial-stewardship requirements.

The FDA has not restored broad branded exclusivity. No biosimilar pathway applies because azithromycin is a conventional small molecule rather than a biologic. Abbreviated New Drug Applications, or ANDAs, are the relevant U.S. generic pathway.[4]

Trovafloxacin regulatory status

Trovafloxacin’s regulatory history is commercially dispositive. The FDA’s safety restrictions and Pfizer’s withdrawal removed the product from ordinary outpatient competition. A new entrant would require a regulatory strategy addressing severe hepatotoxicity, restricted use, clinical need, and risk management.

No biosimilar risk applies to either product. Both are small-molecule antibiotics, and any competitive entry would occur through generic-drug pathways or new drug applications rather than biosimilar approval.

What manufacturing and intellectual-property barriers remain?

Azithromycin has manageable manufacturing barriers but difficult economics. Its production requires control of fermentation-derived intermediates, semisynthetic conversion, impurity profiles, polymorphic or solid-state characteristics, and finished-product stability. Suspension products require additional control of taste, particle size, reconstitution, and shelf life.

These manufacturing capabilities can create supplier advantages without creating durable legal exclusivity. The strongest positions belong to companies with:

• Qualified API sources.
• Multiple production sites.
• Validated analytical methods.
• Regulatory approvals in several markets.
• Reliable pediatric and injectable capacity.
• Distribution agreements with large buyers.

Trovafloxacin has a more severe barrier. Manufacturing know-how is not the primary issue. The central obstacle is regulatory acceptability and commercial demand.

What litigation and settlement activity affects these drugs?

Azithromycin’s major litigation significance was concentrated around generic entry and patent challenges during the loss-of-exclusivity period. The current market is not defined by active, broad patent litigation involving the core molecule. Any remaining dispute would likely involve a formulation, process, labeling, or narrow use claim.

Trovafloxacin’s principal legal and financial exposure arose from product safety, regulatory action, and associated liability rather than sustained generic patent litigation. The withdrawal materially reduced the value of future patent enforcement.

No major current Paragraph IV campaign is commercially central to ordinary azithromycin or trovafloxacin products. For azithromycin, any Paragraph IV dispute would likely concern a specific later-listed formulation or use. For trovafloxacin, a Paragraph IV challenge would have little economic value without a viable market.

What is the revenue outlook for each drug?

Azithromycin should continue generating industry-wide revenue through generic volume, but the revenue pool is structurally limited by price competition. Growth is more likely to come from geographic expansion, supply disruptions, new dosage forms, or institutional contracts than from price increases.

Trovafloxacin has no credible revenue recovery case under its historical profile. A relaunch would require a new regulatory and clinical proposition, not merely a patent or manufacturing strategy.

Outlook category	Azithromycin dihydrate	Trovafloxacin mesylate
Near-term volume	Stable with seasonal variation	Negligible
Price trend	Low and competitive	Not commercially established
Margin profile	Low, dependent on scale	Unattractive
Growth driver	Geographic and channel expansion	None under existing status
Regulatory catalyst	Limited	Would require major safety reassessment
Investment profile	Commodity generic	Abandoned or highly distressed asset

Key Takeaways

• Azithromycin dihydrate is a mature, globally distributed generic antibiotic with continuing volume demand and limited pricing power.
• Pfizer’s Zithromax franchise lost broad exclusivity after core patent expiry in the early 2000s.
• Residual azithromycin patent value is concentrated in formulations, processes, devices, and narrow uses.
• Generic competition, procurement pressure, and antimicrobial stewardship define current economics.
• COVID-19 produced a temporary azithromycin demand increase that later normalized.
• Trovafloxacin mesylate has no meaningful current commercial market after severe hepatotoxicity concerns and regulatory restrictions.
• Trovafloxacin’s primary barrier is regulatory and clinical risk, not patent protection.
• Neither product presents biosimilar competition because both are small-molecule drugs.
• Azithromycin remains a viable manufacturing-scale product; trovafloxacin does not present a conventional generic-entry opportunity.

FAQs

Can azithromycin still support a profitable generic business?

Yes, but profitability depends on manufacturing scale, reliable supply, low API cost, and access to institutional or retail distribution. Standard tablets typically offer limited margin.

Does azithromycin have active composition-of-matter patent protection?

No broad composition-of-matter protection remains for ordinary azithromycin products in the United States. Any surviving rights are narrower and product-specific.

Could a company relaunch trovafloxacin mesylate?

A relaunch would face substantial regulatory and clinical obstacles because of severe hepatotoxicity. Patent ownership alone would not create a viable commercial opportunity.

Are azithromycin shortages a significant investment catalyst?

Shortages can create temporary pricing and volume opportunities for approved suppliers, but they do not usually change the long-term commodity structure of the market.

Which drug has the stronger long-term commercial position?

Azithromycin has the stronger position by a wide margin because it retains broad regulatory approval, recurring demand, multiple dosage forms, and an established generic supply chain.

References

1. U.S. Food and Drug Administration. (2023). Zithromax (azithromycin) prescribing information.
2. U.S. Food and Drug Administration. (2021). COVID-19: Treatment guidelines and antimicrobial use considerations.
3. U.S. Patent No. 4,517,359. (1985). Erythromycin derivatives. United States Patent and Trademark Office.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (1997). Trovan (trovafloxacin mesylate) approval letter and prescribing information.
6. U.S. Food and Drug Administration. (1999). FDA public health advisory: Trovan and liver toxicity.
7. European Medicines Agency. (1999). Trovafloxacin and alatrofloxacin regulatory review and safety restrictions.